14.06.2011
- Biotech deals in the $1 billion to $5 billion range are likely to be a sweet spot for drug companies looking to bolster their pipelines through M&A in an increasingly tough...
14.04.2011
- Sanofi-Aventis said it was considering "strategic alternatives" for its U.S. dermatology business, as it seeks to refocus its business on growth areas such as diabetes and cancer...
11.04.2011
- Sanofi-Aventis said it has completed its takeover of U.S. biotechnology company Genzyme. The companies agreed in February on a deal worth about $20.1 billion. The acquisition gives...
04.04.2011
- French drugmaker Sanofi-Aventis completed its improved $20.1 billion offer for Genzyme allowing it to begin merging the U.S. biotech into its business and add rare diseases to its...
30.03.2011
- Certificates related to Sanofi-Aventis's $20.1 billion acquisition of U.S. biotech firm Genzyme could begin trading on Nasdaq as soon as April 4, depending on the outcome of its...
